The utility of clinical decision tools for diagnosing osteoporosis in postmenopausal women with rheumatoid arthritis

被引:13
|
作者
Brand, Caroline [1 ,2 ,3 ]
Lowe, Adrian [1 ]
Hall, Stephen [4 ]
机构
[1] Royal Melbourne Hosp, Clin Epidemiol & Hlth Serv Evaluat Unit, Parkville, Vic 3052, Australia
[2] Royal Melbourne Hosp, Dept Rheumatol, Parkville, Vic 3052, Australia
[3] Monash Univ, Ctr Res Excellence Patient Safety, Clayton, Vic 3800, Australia
[4] Cabrini Hosp Malvern, Dept Rheumatol, Malvern, Vic 3144, Australia
关键词
D O I
10.1186/1471-2474-9-13
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Patients with rheumatoid arthritis have a higher risk of low bone mineral density than normal age matched populations. There is limited evidence to support cost effectiveness of population screening in rheumatoid arthritis and case finding strategies have been proposed as a means to increase cost effectiveness of diagnostic screening for osteoporosis. This study aimed to assess the performance attributes of generic and rheumatoid arthritis specific clinical decision tools for diagnosing osteoporosis in a postmenopausal population with rheumatoid arthritis who attend ambulatory specialist rheumatology clinics. Methods: A cross-sectional study of 127 ambulatory post-menopausal women with rheumatoid arthritis was performed. Patients currently receiving or who had previously received bone active therapy were excluded. Eligible women underwent clinical assessment and dual-energy-xray absorptiometry (DXA) bone mineral density assessment. Clinical decision tools, including those specific for rheumatoid arthritis, were compared to seven generic post-menopausal tools to predict osteoporosis (defined as T score < -2.5). Sensitivity, specificity, positive predictive and negative predictive values and area under the curve were assessed. The diagnostic attributes of the clinical decision tools were compared by examination of the area under the receiver-operator-curve. Results: One hundred and twenty seven women participated. The median age was 62 (IQR 56-71) years. Median disease duration was 108 (60-168) months. Seventy two (57%) women had no record of a previous DXA examination. Eighty (63%) women had T scores at femoral neck or lumbar spine less than -1. The area under the ROC curve for clinical decision tool prediction of T score < -2.5 varied between 0.63 and 0.76. The rheumatoid arthritis specific decision tools did not perform better than generic tools, however, the National Osteoporosis Foundation score could potentially reduce the number of unnecessary DXA tests by approximately 45% in this population. Conclusion: There was limited utility of clinical decision tools for predicting osteoporosis in this patient population. Fracture prediction tools that include risk factors independent of BMD are needed.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Value of clinical factors in selecting postmenopausal women with rheumatoid arthritis for bone densitometry
    Nolla, JM
    Fiter, J
    Gómez-Vaquero, C
    Alegre, JJ
    Valverde, J
    Roig-Escofet, D
    ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (08) : 799 - 801
  • [22] Clinical and Cardiometabolic Effects of Reducing Sedentary Behavior in Postmenopausal Women with Rheumatoid Arthritis
    Pinto, Ana jessica
    Meireles, Kamila
    Pecanha, Tiago
    Mazzolani, Bruna caruso
    Smaira, Fabiana infante
    Rezende, Diego
    Benatti, Fabiana braga
    Ribeiro, Ana Cristina De Medeiros
    Pinto, Ana Lucia De Sa
    Lima, Fernanda rodrigues
    Roschel, Hamilton
    Gualano, Bruno
    MEDICINE & SCIENCE IN SPORTS & EXERCISE, 2025, 57 (01) : 23 - 32
  • [23] OSTEOPOROSIS, SARCOPENIA AND OSTEOSARCOPENIA IN WOMEN WITH RHEUMATOID ARTHRITIS
    Feklistov, A.
    Demin, N.
    Toroptsova, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1340 - 1340
  • [24] RISK FACTORS FOR OSTEOPOROSIS IN WOMEN WITH RHEUMATOID ARTHRITIS
    Rudenka, A.
    Skrynnik, L.
    Kozlova, V.
    Rudenka, E.
    Babak, G.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S533 - S534
  • [25] Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis
    Reginster, J. -Y.
    Gieschke, R.
    CURRENT DRUG METABOLISM, 2006, 7 (07) : 827 - 836
  • [26] ASSOCIATION OF SERUM URIC ACID LEVEL WITH BONE MINERAL DENSITY AND OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS
    Koh, J. H.
    Lee, S. -G.
    Lee, H. -N.
    Kim, E.
    Sohn, D. H.
    Kim, Y.
    Kim, G. -T.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1620 - 1620
  • [27] OSTEOPOROSIS IN RHEUMATOID-ARTHRITIS - CLINICAL IMPLICATIONS
    KALLA, AA
    MEYERS, OL
    PARKYN, ND
    KOTZE, T
    SOUTH AFRICAN MEDICAL JOURNAL, 1988, 74 (06): : 297 - 297
  • [28] OSTEOPOROSIS IN RHEUMATOID-ARTHRITIS - THE CLINICAL VIEWPOINT
    WOOLF, AD
    BRITISH JOURNAL OF RHEUMATOLOGY, 1991, 30 (02): : 82 - 84
  • [29] Performance of Osteoporosis Risk Assessment Tools in Iranian Postmenopausal Women
    Dabbaghmanesh, M. H.
    Sabet, R. B.
    Aria, A. A.
    Omrani, G. R.
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2007, 5 (01) : 26 - 32
  • [30] Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis
    Stubelius, Alexandra
    Andreasson, Emil
    Karlsson, Anna
    Ohlsson, Claes
    Tivesten, Asa
    Islander, Ulrika
    Carlsten, Hans
    CLINICAL IMMUNOLOGY, 2011, 140 (01) : 37 - 46